Anebulo Pharmaceuticals Inc Quick Ratio (ANEB) starting from the second quarter 2025 to second quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Anebulo Pharmaceuticals Inc   (NASDAQ: ANEB)

Anebulo Pharmaceuticals Inc 's Quick Ratio

ANEB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2025, Quick Ratio fell to 6.09 below Anebulo Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 164 other companies have achieved higher Quick Ratio than Anebulo Pharmaceuticals Inc in second quarter 2025. While Quick Ratio total ranking in the second quarter 2025 has deteriorated compared to the prior quarter from 265 to 700.

Explain Quick Ratio?
How much Cash & cash equivalents ANEB´s has?
What are ANEB´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ANEB Quick Ratio (Dec 31 2025)
Q2		 (Sep 30 2025)
Q1		 (Jun 30 2025)
Q4		 (Mar 31 2025)
Q3		 (Dec 31 2024)
Q2
Y / Y Current Liabilities Change 69.05 % 69.32 % 87.15 % -45.95 % -13.3 %
Y / Y Cash & cash equivalent Change -39.72 % 637.41 % 275.8 % 158.01 % 125.73 %
Quick Ratio MRQ 6.09 10.74 23.84 24.32 17.07
ANEB's Total Ranking # 700 # 265 # 98 # 100 # 170
Seq. Current Liabilities Change 54.14 % 97.63 % -10.69 % -37.87 % 54.39 %
Seq. Cash & cash equivalent Change -12.68 % -10.95 % -12.44 % -11.46 % 968.11 %



Quick Ratio second quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 165
Healthcare Sector # 263
Overall Market # 700


Quick Ratio Statistics
High Average Low
360.58 48.6 2.47
(Dec 31 2021)   (Sep 30 2024)




Financial Statements
Anebulo Pharmaceuticals Inc 's Current Liabilities $ 1 Millions Visit ANEB's Balance sheet
Anebulo Pharmaceuticals Inc 's Cash & cash equivalent $ 9 Millions Visit ANEB's Balance sheet
Source of ANEB's Sales Visit ANEB's Sales by Geography


Cumulative Anebulo Pharmaceuticals Inc 's Quick Ratio

ANEB's Quick Ratio for the trailling 12 Months

ANEB Quick Ratio

 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 28.11 % 0.79 % -17.3 % -40.81 % -36.62 %
Y / Y Cash & cash equivalent TTM Growth 79.78 % 208.54 % 76.49 % 3.86 % -39.27 %
Quick Ratio TTM 12.72 17.47 16.65 14.54 9.06
Total Ranking TTM # 3786 # 0 # 0 # 0 # 0
Seq. Current Liabilities TTM Growth 21.1 % 15.9 % 10.07 % -17.08 % -4.72 %
Seq. Cash & cash equivalent TTM Growth -11.85 % 21.67 % 26.04 % 33 % 51.28 %

Quick ratio ranking by company, industry and sector >> Back to ANEB Financial Strength Comparisons >> Go to Compare ANEB Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q2 2025 to $1.49 millions, cumulative Quick Ratio decreased to 12.72 below the Anebulo Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 461 other companies have achieved higher Quick Ratio than Anebulo Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2025 from 0 to 3786.

Explain Quick Ratio?
How much Cash & cash equivalents ANEB´s has?
What are ANEB´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 462
Healthcare Sector # 921
Within the Market # 3786


trailing twelve months Quick Ratio Statistics
High Average Low
54.39 33.56 12.72
(Jun 30 2022)   (Dec 31 2025)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Neurogene Inc   16.39 $ 269.013  Millions$ 16.411  Millions
Xbiotech Inc   15.83 $ 125.551  Millions$ 7.929  Millions
Tango Therapeutics Inc   15.83 $ 343.138  Millions$ 21.679  Millions
Mira Pharmaceuticals Inc   15.71 $ 11.030  Millions$ 0.702  Millions
Phio Pharmaceuticals Corp  15.69 $ 21.031  Millions$ 1.340  Millions
Alto Neuroscience Inc   15.58 $ 176.484  Millions$ 11.325  Millions
Veradermics Inc  15.50 $ 141.862  Millions$ 9.152  Millions
Ocular Therapeutix Inc   15.36 $ 737.060  Millions$ 47.989  Millions
Nuvalent Inc   15.05 $ 1,371.952  Millions$ 91.171  Millions
Mereo Biopharma Group Plc  14.66 $ 41.387  Millions$ 2.824  Millions
Bioharvest Sciences Inc   14.57 $ 46.050  Millions$ 3.160  Millions
Immunome Inc   14.55 $ 654.782  Millions$ 44.990  Millions
Eupraxia Pharmaceuticals Inc   14.51 $ 80.563  Millions$ 5.551  Millions
Climb Bio Inc   14.47 $ 101.080  Millions$ 6.984  Millions
Synlogic Inc   14.41 $ 14.668  Millions$ 1.018  Millions
Cervomed Inc   14.35 $ 20.864  Millions$ 1.454  Millions
Bicara Therapeutics Inc   14.33 $ 414.801  Millions$ 28.949  Millions
Tyra Biosciences Inc   14.15 $ 256.003  Millions$ 18.094  Millions
Rezolute Inc   14.09 $ 167.858  Millions$ 11.912  Millions
Cogent Biosciences Inc   14.08 $ 900.765  Millions$ 63.953  Millions
Keros Therapeutics Inc   14.08 $ 287.415  Millions$ 20.414  Millions
Amylyx Pharmaceuticals Inc   13.97 $ 316.979  Millions$ 22.688  Millions
Oric Pharmaceuticals Inc   13.79 $ 281.488  Millions$ 20.417  Millions
Vtv Therapeutics Inc   13.39 $ 88.932  Millions$ 6.641  Millions
Agios Pharmaceuticals Inc   13.39 $ 854.425  Millions$ 63.814  Millions
Vera Therapeutics Inc   13.37 $ 714.589  Millions$ 53.455  Millions
Chemocentryx Inc.  13.22 $ 0.736  Millions$ 0.056  Millions
Dianthus Therapeutics Inc   13.16 $ 404.295  Millions$ 30.732  Millions
Novo Nordisk A  12.96 $ 761.785  Millions$ 58.768  Millions
Rallybio Corporation  12.96 $ 54.736  Millions$ 4.223  Millions

Date modified: 2026-09-12T06:25:51+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.